Skip to main content
. 2023 Mar 31;253:115311. doi: 10.1016/j.ejmech.2023.115311

Fig. 1.

Fig. 1

A) First-in-class 3CLpro inhibitor nirmatrelvir 1 approved as active component of the oral drug Paxlovid® for COVID-19 treatment; B) representative examples of peptidomimetic inhibitors (2–4) of 3CLpro from different CoVs repurposed on SARS-CoV-2.